Spondyloarthritis & psoriatic arthritis
Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)
Authors' conclusion
Following its approval in France, ~59% of axSpA patients retained secukinumab in daily practice, at 1 year. Prior exposure to TNFi, OSI and IBD were identified as risk factors for secukinumab discontinuation.
Study context
- Population
- Adult axial spondyloarthritis (axSpA) patients who received secukinumab in France between 11 August 2016 and 31 August 2018
- Participants
- 906 patients48 centres
- Exposure
- axSpA patients with vs without objective signs of inflammation (OSI) on secukinumab
- Outcome
- Secukinumab retention (Kaplan-Meier (KM)) by OSI
- Follow-up
- 1 year
Methodological detailsmulticentric, non-interventional, Kaplan-Meier analysis, multivariate analysis
- Multicentric
- Non-interventional
- Kaplan-Meier analysis
- Multivariate analysis
Main finding
As reported in the abstract
1-year KM retention rate of secukinumab
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| 1-year KM retention rate of secukinumab, overall | Secukinumab 59% (95% CI 55%–62%) |
Factors associated with better 1-year secukinumab retention (multivariate analysis)
- No prior tumour necrosis factor inhibitor (TNFi) exposure associated with better retention
- Absence of OSI associated with better retention
- Inflammatory bowel disease (IBD) associated with better retention
Original publication
Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA). RMD Open. Published 15 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →